lymphoma transplantation regimen for relapsed and refractory non-Hodgkin Outcomes after alemtuzumab-containing reduced-intensity allogeneic
暂无分享,去创建一个
C. Craddock | S. Mackinnon | K. Peggs | A. Hunter | D. Linch | R. Chopra | G. Cook | P. Mahendra | E. Morris | D. Milligan | A. Parker | G. Smith | S. Schey | J. Tighe | C. Hatton | Chris Hatton | G. Smith